Pfizer (PFE) Reports FDA Accepts & Grants Priority Review to sNDA for BRAFTOVI (encorafenib) in Combination with ERBITUX (cetuximab) (BRAFTOVI Doublet) - StreetInsider.com

Pfizer (PFE) Reports FDA Accepts & Grants Priority Review to sNDA for BRAFTOVI (encorafenib) in Combination with ERBITUX (cetuximab) (BRAFTOVI Doublet)  StreetInsider.com